Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
about
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancerSuppression of miR-4735-3p in androgen receptor-expressing prostate cancer cells increases cell death during chemotherapy.Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner.Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division.Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer
P2860
Q37022317-D024A500-1021-4E6B-925F-53A9C923FF9EQ38598782-8AEDC86D-1A2F-4029-AF43-A7EBFF93B461Q40690647-C969CBED-EA61-4C50-94C5-76A08329BDE0Q41045664-ED1C1F1A-5CAA-40F8-AD03-16B844DFFFA3Q48690318-84224E9E-C605-416D-8597-AE4EA456E0E3Q55482080-3782381A-8557-41A5-A35E-7F9CFAAF1A35Q58709227-68337C65-6676-4162-99B3-3D5B57790C22
P2860
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@ast
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@en
type
label
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@ast
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@en
prefLabel
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@ast
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@en
P2093
P2860
P356
P1433
P1476
Anti-cancer efficacy of SREBP ...... ancer harboring p53 mutations.
@en
P2093
Jason Boyang Wu
Leland W K Chung
Wen-Chin Huang
Xiangyan Li
P2860
P304
41018-41032
P356
10.18632/ONCOTARGET.5879
P407
P577
2015-10-16T00:00:00Z